Evidence map›Paper›PMID 42209734›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2026

Pristimerin enhances erastin-induced ferroptosis in AML cells via the ATF3/SLC7A11 axis.

Shan Chen, Liang Zhong, Liran Liu, Zhiyin Ke, Yi Zhao, Peng Wan, Ying Zhang, Yang Liao, Ying Deng, Lihua Yu and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Shan ChenClinical Laboratory, the Affiliated Yongchuan Hospital of Chongqing Medical University, Chongqing, 402160, China.
Liang ZhongKey Laboratory of Laboratory Medical Diagnostics, Ministry of Education, Department of Laboratory Medicine, Chongqing Medical University, Chongqing, 400016, China.
Liran LiuClinical Laboratory, the Affiliated Yongchuan Hospital of Chongqing Medical University, Chongqing, 402160, China.
Zhiyin KeClinical Laboratory, the Affiliated Yongchuan Hospital of Chongqing Medical University, Chongqing, 402160, China.
Yi ZhaoClinical Laboratory, the Affiliated Yongchuan Hospital of Chongqing Medical University, Chongqing, 402160, China.
Peng WanClinical Laboratory, the Affiliated Yongchuan Hospital of Chongqing Medical University, Chongqing, 402160, China.
Ying ZhangClinical Laboratory, the Affiliated Yongchuan Hospital of Chongqing Medical University, Chongqing, 402160, China.
Yang LiaoClinical Laboratory, the Affiliated Yongchuan Hospital of Chongqing Medical University, Chongqing, 402160, China.
Ying DengClinical Laboratory, the Affiliated Yongchuan Hospital of Chongqing Medical University, Chongqing, 402160, China.
Lihua YuClinical Laboratory, the Affiliated Yongchuan Hospital of Chongqing Medical University, Chongqing, 402160, China. yulihuacool@163.com.
Beizhong LiuClinical Laboratory, the Affiliated Yongchuan Hospital of Chongqing Medical University, Chongqing, 402160, China. liubeizhong@cqmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute myeloid leukemia (AML) is a highly aggressive hematologic malignancy predominantly seen in adults, with chemotherapy remaining the primary modality for its clinical management. Nevertheless, the efficacy of chemotherapy is often compromised by issues such as drug resistance, toxicity, and long-term adverse effects, particularly in refractory and relapsed patients. Natural products have historically served as a vital source for the development of anti-cancer agents. In this study, we examined the therapeutic potential of pristimerin (PM), a natural bioactive compound derived from the Malvaceae and Portulacaceae families, against acute myeloid leukemia and explored its underlying mechanisms. Our findings indicate that PM effectively suppressed AML cell proliferation, triggered apoptosis, and arrested the cell cycle at the G0/G1 phase. Furthermore, PM was found to enhance erastin-induced ferroptosis via modulation of the ATF3/SLC7A11 axis, characterized by increased iron (Fe

Indexed as

Activating Transcription Factor 3Amino Acid Transport System y+Antineoplastic AgentsFerroptosisLeukemia, Myeloid, AcutePentacyclic TriterpenesPiperazinesTriterpenesApoptosisCell Line, TumorCell ProliferationHumansActivating Transcription Factor 3Amino Acid Transport System y+Antineoplastic AgentsATF3 protein, humancelastrolerastinPentacyclic TriterpenesPiperazinesTriterpenesAcute myeloid leukemiaATF3/SLC7A11ErastinPristimerin

Identifiers

PMID42209734

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.